



Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

December 9, 2020

www.biocon.com

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code- 532523	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 050 Scrip Symbol- Biocon
---	---

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations').

Dear Sir/ Madam,

Further to our intimation dated November 7, 2020, in relation to execution of a Securities subscription agreement ("SSA") and a shareholders' agreement ("SHA") between Biocon Limited (the "Company"), Biocon Biologics Limited ("BBL"), existing investors of BBL and Goldman Sachs India AIF Scheme - 1, a scheme setup under Goldman Sachs India Alternative Investment Trust, acting through its investment manager, Goldman Sachs (India) Alternative Investment Management Private Limited (the "Investor") as applicable, we wish to inform you that the subscription money aggregating to Rs. 1,125 Crores have been received by BBL from the Investor.

Consequently, today the Board of BBL has approved the allotment of 1,125 Unlisted, Unsecured, Redeemable, Optionally Convertible Debentures (OCDs) at face value of Rs. 1,00,00,000 (Rupees One Crore) each aggregating to Rs. 1,125 Crores of BBL to the Investor.

This intimation is being made in compliance with Regulations 30, read with Schedule III and other applicable regulations of the SEBI Listing Regulations.

We request you to take this on record and that the same be treated as compliance under the applicable regulation(s).

Thanking you,

Yours faithfully,

For Biocon Limited



Mayank Verma

② **Mayank Verma**
Company Secretary and Compliance Officer